Aldeyra Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Aldeyra Therapeutics sits in the top decile of US sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count).
Aldeyra Therapeutics: 26 sponsored US clinical trials, 1 recruiting.
Aldeyra Therapeutics sponsors 26 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 25 completed. 10 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye, with 2 trials.
Top-decile sponsor footprint
Aldeyra Therapeutics ranks in the top decile of sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
25 of 25 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
26 total, page 1 of 1
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
NCT07402876
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
NCT06685692
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT06493604
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT06424444
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
NCT05717920
A Study in Subjects With Retinitis Pigmentosa
NCT05392179
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
NCT05392192
A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels
NCT05487404
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
NCT05062330
A Clinical Trial to Assess Subjects With Dry Eye Disease.
NCT04971031
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
NCT04908514
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.
NCT04847544
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
NCT04735393
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
NCT04674358
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
NCT04136366
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
NCT03916042
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT03879863
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
NCT03660878
RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
NCT03445650
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
NCT03494504
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
NCT03404115
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
NCT03162783
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
NCT03131154
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
NCT03012165
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
NCT02402309
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
NCT02406209
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 14 |
| Phase 3 | 10 |
Therapeutic Areas
What is open in the Aldeyra Therapeutics pipeline
1 recruiting of 26 indexed (4% open); 25 completed (96%).
Phase mix: 10 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Dry Eye (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Aldeyra Therapeutics: open-pipeline peers nationwide
Peers matched on 26 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Aldeyra Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 26 trials (± recruiting share)
- Abbott Diabetes Care · 26 trials · 12% recruiting
- California Polytechnic State University-San Luis Obispo · 26 trials · 19% recruiting
- DexCom · 26 trials · 4% recruiting
- Harvard Medical School (HMS and HSDM) · 26 trials · 15% recruiting
Sponsors near 4% open enrollment (± trial volume)
- MaineHealth · 4% recruiting · 26 trials
- Medtronic Spinal and Biologics · 4% recruiting · 26 trials
- Oklahoma State University · 4% recruiting · 26 trials
- ViiV Healthcare · 4% recruiting · 182 trials
Related
What to do with this Aldeyra Therapeutics page
26 registered trials is a research-attention snapshot, not an endorsement of Aldeyra Therapeutics or any single study.
- 1 of Aldeyra Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dry Eye is the condition Aldeyra Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Aldeyra Therapeutics pipeline card: 26 registered trials from official public datasets.Report a data error.